StockWatch
·
GODAVARI BIOREFINERIES LTD · QQ2 FY-2027 · THE CALL

Chemicals boom masks consolidated loss drag

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsGODAVARIBGodavari Biorefineries Ltd13 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

Beat Q2 chemicals guidance (₹204 vs ₹190 Cr). Sugar losses persist; no FY27/FY28 consolidated profit target disclosed.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Godavari's bio-chemicals division delivered a beat (₹204.2 Cr vs ₹190 Cr guidance, +38.8% YoY) with expanding margins (10.8%, +60 bps), validating the debottlenecking strategy. However, consolidated loss remains material at -₹15.2 Cr (NPM -2.8%), dragged by a loss-making sugar/ethanol segment (₹19.3 Cr EBITDA loss). The ₹240 Cr quarterly chemicals target by FY28 is ambitious and unproven; management offered no credible profitability timeline for the overall business.

₹549.2 Cr

Revenue · +27.5% YoY

₹-15.2 Cr

Reported PAT · +null% YoY

Compressing

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

Bio-chemicals revenue ₹204.2 Cr, beat ₹190 Cr guidance

MET

Delivered ₹204.2 Cr vs ₹190 Cr expected; +7.5% beat, +38.8% YoY growth vs Q2 FY26 ₹147 Cr

Bio-chemicals EBITDA margin improved to 10.8% from 10.2%

MET

EBITDA ₹22.1 Cr ÷ ₹204.2 Cr revenue = 10.83%, up 60 bps confirmed; +47% YoY in rupees

Consolidated net loss narrowed to ₹15.2 Cr from ₹41.6 Cr YoY

MET

Q2 FY26 loss -₹41.6 Cr, Q2 FY27 loss -₹15.2 Cr; 63.4% improvement in loss magnitude. Still loss, not profit.

₹240 Cr quarterly chemicals revenue achievable by FY28

OVERSTATED

Currently ₹204.2 Cr; requires 17.6% CAGR over ~5 quarters. Dependent on ₹25 Cr debottlenecking investment not yet validated. Projection, not committed.

Consolidated operations moving toward profitability

MISS

Consolidated NPM -2.8% in Q2 FY27 (vs -3.5% in H1 FY26 average). Sugar/ethanol segment lost ₹19.3 Cr EBITDA in Q2 (61% of revenue). No profit timeline disclosed.

Earnings quality

What changed since the last call

Deltas vs. the prior call

Bio-chemicals beat Q2 guidance by ₹14.2 Cr

Upgrade

Q2 FY27 ₹190 Cr guidance → ₹204.2 Cr delivered. Driven by higher volumes from debottlenecking initiatives and crisis-driven Hormuz area sales. This is a beat this quarter, not a multiyear guidance raise.

Consolidated loss narrowed, not profitability achieved

Neutral

Loss shrunk from -₹41.6 Cr (Q2 FY26) to -₹15.2 Cr (Q2 FY27), a 63.4% improvement in loss magnitude. But NPM remains -2.8%. No path to breakeven disclosed; management deferred to H2 seasonality.

₹240 Cr/qtr chemicals target timeline reaffirmed

Neutral

Same FY28 target and ₹25 Cr investment reconfirmed from Q1 guidance. No acceleration or new milestones added. Debottlenecking in progress but not yet revenue-visible above Q2's ₹204 Cr.

Sugar/ethanol segment loss persists despite distillery commissioning

Downgrade

Q2 FY27 sugar segment EBITDA loss ₹19.3 Cr (vs ₹23.1 Cr in Q2 FY26, improvement of ₹3.8 Cr). Grain-based distillery commissioned Q1, now operational, but ethanol economics weak due to feedstock constraints and monsoon failure in Maharashtra/Karnataka.

The Q&A

Moderate. Analysts pressed on profitability timeline, feedstock risks, and inventory volatility. Management held steady on strategy but offered hedges: 'H2 is seasonally stronger,' 'feedstock landscape evolving,' 'debottlenecking in progress.' Q&A was candid on challenges but vague on consolidated profit recovery.

The exchanges that mattered

Bio-chemicals guidance beat — Vivek Gupta, Star Investments

Answered

Combination of increased volumes from debottlenecking investments done, and higher prices from Hormuz crisis. ₹204 Cr also includes ₹140 Cr legacy baseline (vs ₹147 Cr Q2 FY26), so net ₹60 Cr incremental from new chemicals and higher realization.

Profitability timeline and initiatives — Kranti, WealthMills Securities

Answered

Bio-chemicals will drive profitability (already ~90% of segment EBITDA from chemicals in H1). Sugar-ethanol is seasonal; H2 is profitable. DME pilot March 2027. TNBC trials starting soon (6-9 month preliminary results). ₹240 Cr/qtr target by FY28 will bring consolidated improvement.

Drug discovery capex and strategy — Nivesh Verma, Verxora Securities

Answered

Preliminary efficacy budget ₹15-20 Cr. Not a pharma company, so will out-license molecule to pharma companies post-trials for clinical development. Strategy is to derisk early-stage and partner.

Feedstock and ethanol facility flexibility — Nivesh Verma, Verxora Securities

Answered

800 kL/day total distillery capacity. Grain-based facility enables maize and rice processing; cane-based ethanol flexible. Government restricted sugarcane juice diversion to ethanol (favoring sugar); company adapting by using molasses, grain. Multi-feedstock strategy reduces mono-feedstock risk and aligns with government E20 blending goal.

Chemicals EBITDA margin and growth proportion — Hitesh Agarwal, Investment Partners

Partial

Incremental margin comes from specialty chemicals (ethyl acetate, higher-volume molecules) and debottlenecking. ₹190 Cr→₹240 Cr progression expected to yield further margin expansion as scale improves and mix shifts to specialty products.

Inventory decline and working capital — Hitesh Agarwal, Investment Partners

Answered

Purely seasonal. March (Q4) has peak sugar stocks; September (Q2) has lower stocks due to processing cycle. Chemical inventory grows pro-rata with business; nothing structural to read.

Feedstock procurement and agricultural strategy — Suhani Singh, ROS Capital

Answered

Multi-feedstock strategy key. Working with farmers via Agriculture Research Station for high-yield varieties and regenerative practices. Maize prices high but locked in for ethanol blending via ENA (ethanol for OMCs). Sugar economics improving if prices move up due to tighter market. Rice sourcing via PCI scheme. Each feedstock has different economics; company optimizing mix.

Chemicals volume vs. realization and specialty share — Snehil Surana, Star Broking

Answered

Mix of both. ₹147 Cr Q2 FY26 → ₹204.2 Cr Q2 FY27 = ₹57 Cr net growth. Partly from existing chemicals scaling (volume + some price from debottlenecking benefit), partly from specialty chemical mix in H1 (52% of H1 revenue is specialty). New specialty chemicals launching April-September 2027 from ₹25 Cr capex will further shift mix.

Ethanol and sugar economics — Varun Mishra, SG Capital

Partial

Long answer on feedstock dynamics. Grain prices can be high, but hedged via ENA (ethanol for OMCs) contracts. Sugar market expected to tighten due to reduced B-molasses diversion from ethanol policy; should support sugar price uplift. Monsoon risks persist; droughts likely every few years, but company diversifying feedstock to insulate.

Capex allocation and debottlenecking priority — Varun Mishra, SG Capital

Answered

₹25 Cr is primarily bio-chemicals debottlenecking (acid base capacity, de-bottlenecking across 20-25 specialty chemicals). Ethanol facility optimizations are minor capex; major investments deferred pending larger off-take agreements from customers.

PAT profitability timeline — Varun Mishra, SG Capital

Dodged

History shows Q3/Q4 are strong (seasonal sugar profitability). Company expects modest improvement in H2 FY27. PAT positive depends on sugar price realization and chemicals debottlenecking delivering on ₹240 Cr target by FY28. No specific FY year committed.

Grain-based distillery operational status — Snehil Surana, Star Broking

Answered

Commissioned end of Q1 (end of June). Now operational to meet orders from oil companies for ethanol blending. Taking contracts, meeting delivery schedules. Facility operational and functional for ethanol-based program.

Guidance

Forward guidance and management's confidence

Bio-based chemicals ₹240 Cr/quarter by FY28 (vs ₹204.2 Cr Q2 FY27)

Medium

Target supported by ₹25 Cr debottlenecking investment ongoing through 2027. Requires ~17.6% CAGR over next 5 quarters. Achieved in 20-25 new specialty chemical products.

Bio-chemicals EBITDA margin to improve toward double-digits as volume scales and product mix shifts to specialty

Medium

Currently 10.8% (Q2 FY27). Management expects incremental margin as ₹190 Cr→₹240 Cr progression scales and higher-value molecules ramp. No specific percentage target.

₹25 Cr capex for bio-chemicals debottlenecking and multi-feedstock ethanol facility optimization

High

₹25 Cr debottlenecking capex announced Q1 FY27; deployed through H1-H2. Majority for bio-chemicals acid base and specialty capacity. Ethanol facility minor optimization ongoing.

Risks the call surfaced

Ranked by how much they should concern a holder

Profitability & leverage

High

Company lost ₹15.2 Cr in Q2 FY27 despite 27.5% revenue growth. Sugar/ethanol segment drag (₹19.3 Cr EBITDA loss) masks chemicals strength. Management deferred profitability recovery to 'H2' with no quantified target.

Feedstock & seasonality

High

Maharashtra/Karnataka drought affected sugar/ethanol production. Government restricted sugarcane juice diversion to ethanol, favoring sugar production. Grain prices volatile. Company mitigating via multi-feedstock facility, but economics depend on external supply/policy.

Execution & debottlenecking

Medium

Target ₹240 Cr/qtr bio-chemicals by FY28 assumes debottlenecking yields proportional revenue and margin gains. Q2 beat (₹204 vs ₹190 Cr) is step forward, but ₹240 Cr remains unproven projection. New 20-25 specialty chemicals ramp-up timelines uncertain.

Drug discovery & innovation timelines

Medium

TNBC preliminary efficacy trials expected Q3 FY27; DME pilot March 2027. Trials are early-stage; timeline to clinical approval, manufacturing scale, and revenue uncertain. Drug discovery requires out-licensing, pharma partner selection, regulatory approvals.

Market sentiment & investor confidence

Medium

Consolidated losses erode shareholder value. Q2 loss of ₹15.2 Cr and H1 loss of ₹34.6 Cr may concern value investors. Management did not commit to PAT positive timeline.

Management

Score 6/10. Samir Somaiya (Chairman) articulate on strategy and business model; candid on macro headwinds (monsoon, policy). Ashish Sinha (Deputy GM, IR) clear on financials. Some hedging on timelines; long-winded on feedstock dynamics. Beat Q2 chemicals guidance (₹204 vs ₹190 Cr). Debottlenecking progressing; grain distillery commissioned on time. H1 loss improving (₹34.6 Cr vs ₹57.6 Cr YoY). But consolidated profitability target missing; no clear path to breakeven disclosed.

What to watch next
  • 1 · March 2027

    DME pilot plant trial results (carbon dioxide to dimethyl ether conversion, LPG substitute)

  • 2 · Q3 FY27 (Jul-Sep 2026)

    TNBC triple-negative breast cancer molecule preliminary efficacy trial outcome; path to out-licensing

  • 3 · Apr-Sep 2027

    ₹25 Cr debottlenecking capex to boost bio-chemicals capacity toward ₹240 Cr/qtr run-rate

The ₹240 Cr quarterly chemicals target by FY28 is ambitious and unproven; management offered no credible profitability timeline for the overall business.

Informational and educational content only. Not investment advice.